Pmv Pharmaceuticals, Inc. PMVP
We take great care to ensure that the data presented and summarized in this overview for PMV Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PMVP
View all-
Orbimed Advisors LLC San Diego, CA5.98MShares$8.25 Million0.29% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.29MShares$7.3 Million6.78% of portfolio
-
Tang Capital Management LLC San Diego, CA4.79MShares$6.6 Million0.3% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.3MShares$4.56 Million0.1% of portfolio
-
Sio Capital Management, LLC New York, NY2.64MShares$3.64 Million1.28% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$3.63 Million1.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.16MShares$2.98 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.07MShares$2.85 Million0.01% of portfolio
-
Interwest Venture Management CO1.61MShares$2.23 Million48.05% of portfolio
-
Stonepine Capital Management, LLC Bend, OR1.37MShares$1.89 Million1.56% of portfolio
Latest Institutional Activity in PMVP
Top Purchases
Top Sells
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Insider Transactions at PMVP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 27
2025
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
220,643
+32.85%
|
$220,643
$1.37 P/Share
|
|
Oct 23
2025
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,000
-16.74%
|
$1,000,000
$1.52 P/Share
|
|
Sep 10
2025
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-7.72%
|
$500,000
$1.8 P/Share
|
|
Jul 01
2025
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
33,065
-26.88%
|
$33,065
$1.06 P/Share
|
|
Jul 01
2025
|
Robert Ticktin General Counsel & COO |
SELL
Open market or private sale
|
Direct |
23,151
-19.0%
|
$23,151
$1.06 P/Share
|
|
Jul 01
2025
|
David Henry Mack President and CEO |
SELL
Open market or private sale
|
Direct |
58,411
-9.82%
|
$58,411
$1.06 P/Share
|
|
Jul 01
2025
|
Michael Carulli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
28,249
-31.96%
|
$28,249
$1.06 P/Share
|
|
Jan 03
2025
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,709
+3.11%
|
$0
$0.53 P/Share
|
|
Dec 03
2024
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
91,750
+14.66%
|
$0
$0.53 P/Share
|
|
Sep 11
2024
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,218
-5.75%
|
$7,218
$1.5 P/Share
|
|
Sep 11
2024
|
Michael Carulli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,891
-3.17%
|
$2,891
$1.5 P/Share
|
|
Jan 18
2024
|
Deepika Jalota Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,555
+43.23%
|
-
|
|
Jan 18
2024
|
David Henry Mack President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
163,890
+27.03%
|
-
|
|
Jan 18
2024
|
Michael Carulli Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,220
+47.39%
|
-
|
|
Nov 22
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,786
-100.0%
|
$175,572
$2.23 P/Share
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
BUY
Bona fide gift
|
Indirect |
85,307
+34.04%
|
-
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
SELL
Bona fide gift
|
Direct |
85,307
-23.44%
|
-
|
|
Oct 18
2023
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
198,407
+35.29%
|
$0
$0.53 P/Share
|
|
Sep 15
2023
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,104
-12.05%
|
$24,624
$6.62 P/Share
|
|
Sep 15
2023
|
Leila Alland Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,291
-12.05%
|
$37,746
$6.62 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 238K shares |
|---|
| Open market or private sale | 1.64M shares |
|---|